Moderna Announces Workforce Reduction

Moderna has revealed plans to trim its global workforce by about 10%, which would leave it with less than 5,000 employees by year-end. This move, announced on Thursday, aligns with the company’s goal to cut annual operating expenses by around $1.5 billion by 2027, according to CEO Stéphane Bancel.

The company is navigating a shift in its product line, introducing a new mRNA vaccine that combines Covid and flu protections to counteract a drop in sales from its Covid-19 and respiratory syncytial virus vaccines.

CEO Insights on Company Direction

In a recent communication, Bancel expressed that the decision was challenging, given the impact on employees who have devoted themselves to Moderna’s mission. He extended his gratitude to them for their contributions. Meanwhile, he acknowledged that, while looking to cut costs, it’s essential to maintain focus on research and development, find efficiencies in manufacturing, and renegotiate contracts with suppliers.

Earlier this year, Moderna anticipated that its annual operating expenses for 2027 would fall between $4.7 billion and $5 billion.

Market Challenges

Moderna’s shares have seen a significant decline, over 90% from pandemic highs, prompting the need for reassessment. In his letter, Bancel highlighted that the company has three approved products currently and aims to gain approvals for eight new products in the upcoming three years. Employees are set to receive further details regarding the layoffs in an upcoming meeting this Saturday.

We’re deeply committed to intensifying our focus on innovative solutions for tumors, rare diseases, and emerging viruses, Bancel stated. Meanwhile, Moderna has not provided any immediate comment in response to requests from outside sources.